Which nucleotide and nucleoside analogues are used to treat chronic hepatitis B infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Nucleotide and Nucleoside Analogues for Hepatitis B Treatment

Available Agents

The nucleos(t)ide analogues (NAs) approved for chronic hepatitis B treatment include three nucleoside analogues (lamivudine, telbivudine, and entecavir) and two nucleotide analogues (adefovir dipivoxil and tenofovir disoproxil fumarate/tenofovir alafenamide). 1

Nucleoside Analogues

  • Lamivudine: An L-nucleoside that was the first oral NA approved for hepatitis B, but is associated with high rates of drug resistance (up to 70% after 5 years) 1, 2

  • Telbivudine: Another L-nucleoside with superior efficacy to lamivudine but still carries intermediate resistance rates 1, 3

  • Entecavir: A deoxyguanosine analogue that demonstrates high potency with virological response rates of 67% in HBeAg-positive patients and 90% in HBeAg-negative patients at one year 1, 4

  • Emtricitabine: An L-nucleoside licensed for HIV treatment that also has activity against HBV, though not specifically approved for hepatitis B monotherapy in most regions 1, 5

Nucleotide Analogues (Acyclic Nucleoside Phosphonates)

  • Adefovir dipivoxil: Shows virological response rates of 21% in HBeAg-positive and 51-63% in HBeAg-negative patients at one year, but has been superseded by more potent agents 1, 4

  • Tenofovir disoproxil fumarate (TDF): Demonstrates superior efficacy with 76% virological response in HBeAg-positive and 93% in HBeAg-negative patients at one year 1, 4

  • Tenofovir alafenamide (TAF): A newer formulation with improved renal and bone safety profile, showing 64% response in HBeAg-positive and 94% in HBeAg-negative patients 4

First-Line Treatment Recommendations

Current international guidelines recommend entecavir and tenofovir (TDF or TAF) as first-line therapy due to their superior potency and high genetic barriers to resistance. 3, 4, 6

  • These agents achieve virological suppression (undetectable HBV DNA) in >90% of treatment-adherent patients after 3 years of therapy 3

  • Both demonstrate very low resistance rates with long-term use, unlike earlier generation agents 6, 2

  • Lamivudine, adefovir, and telbivudine are no longer considered first-line options due to inferior efficacy and/or higher resistance profiles 3, 4

Clinical Efficacy by HBeAg Status

HBeAg-Positive Patients (at 1 year)

  • Virological response rates: Entecavir 67%, Tenofovir 74-76%, Telbivudine 60%, Lamivudine 36-40%, Adefovir 21% 1, 4

  • HBe seroconversion rates: Approximately 20% for all NAs, increasing with continued treatment 1

  • HBsAg loss rates: 1-3% at one year (highest with tenofovir at 3%) 1, 4

HBeAg-Negative Patients (at 1 year)

  • Virological response rates: Tenofovir 91-93%, Entecavir 90%, Telbivudine 88%, Lamivudine 72-73%, Adefovir 51-63% 1, 4

  • ALT normalization: 76-83% across most agents 4

  • HBsAg loss: Rare (0%) with all NAs at one year 1, 4

Resistance Patterns and Cross-Resistance

Understanding resistance patterns is critical for selecting rescue therapy when treatment failure occurs. 7

  • Lamivudine-resistant HBV: Maintains sensitivity to nucleotide analogues (adefovir, tenofovir) but shows high-level cross-resistance to other L-nucleosides (emtricitabine, telbivudine, clevudine) 8

  • Adefovir-resistant HBV: Remains sensitive to entecavir and tenofovir, though reduced sensitivity to tenofovir has been demonstrated 7

  • Entecavir-resistant HBV: Maintains susceptibility to adefovir and tenofovir, with no cross-resistance to nucleotide analogues 7

Key Clinical Considerations

Sequential monotherapy should be avoided to prevent multidrug resistance; combination therapy of nucleoside and nucleotide analogues without cross-resistance is strongly recommended when managing resistance. 7

  • Primary treatment failure is defined as inability to reduce HBV DNA by 1 log10 IU/mL after 6 months 9

  • Virological breakthrough requires increase in HBV DNA by 1 log10 above nadir on two occasions one month apart in compliant patients 9

  • Genotypic resistance testing should be performed when virological breakthrough occurs despite good compliance 7

References

2
Research

Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B.

The Journal of antimicrobial chemotherapy, 2011

6
Research

Current developments in nucleoside/nucleotide analogues for hepatitis B.

Expert review of gastroenterology & hepatology, 2014

7
Guideline

kasl clinical practice guidelines: management of chronic hepatitis b.

Clinical and Molecular Hepatology, 2012

Related Questions

What is the appropriate entecavir dosing for an adult with chronic hepatitis B and acute kidney injury based on renal function?
What is the recommended dosing regimen, administration method, and monitoring precautions for Stronger Neo‑Minophagen C (SNMC) in adult patients with chronic hepatitis B or C?
When can antiviral treatment be stopped in a patient with hepatitis B (HBV) infection and normalized liver function tests, who has achieved a sustained virological response with undetectable HBV DNA level?
What are the typical signs and symptoms of measles in vaccinated individuals?
In a man who underwent radical prostatectomy two years ago and has PSA levels consistently between 0.08 and 0.18 ng/mL (never exceeding 0.2 ng/mL), would taking a lycopene supplement be beneficial or harmful?
What are the indications for creating a mucus fistula in a patient?
What is the recommended method to reverse an elevated INR in a patient who is not on anticoagulation therapy?
What is the appropriate evaluation and management for a patient with an acute pop sensation, medial bruising, and elbow pain?
What is the recommended management of panhypopituitarism, including glucocorticoid, thyroid, sex steroid, growth hormone, and diabetes insipidus replacement and monitoring?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.